Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia

NCT00825539 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: AQW051
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals